Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 433 Shares of Eli Lilly and Company (NYSE:LLY)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Eli Lilly and Company (NYSE:LLY) by 0.2% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 175,057 shares of the company’s stock after buying an additional 433 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s portfolio, making the stock its 15th biggest position. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Eli Lilly and Company were worth $136,187,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Castle Rock Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 126.2% during the 4th quarter. Castle Rock Wealth Management LLC now owns 2,357 shares of the company’s stock valued at $1,452,000 after buying an additional 1,315 shares in the last quarter. &PARTNERS lifted its holdings in Eli Lilly and Company by 380.0% in the 4th quarter. &PARTNERS now owns 4,982 shares of the company’s stock worth $2,919,000 after purchasing an additional 3,944 shares in the last quarter. Signature Wealth Management Group purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $561,000. Coho Partners Ltd. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $515,000. Finally, Wedmont Private Capital lifted its holdings in Eli Lilly and Company by 10.5% in the 4th quarter. Wedmont Private Capital now owns 11,198 shares of the company’s stock worth $7,010,000 after purchasing an additional 1,061 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 0.9 %

Shares of LLY traded down $8.86 during midday trading on Tuesday, reaching $941.60. 2,093,839 shares of the stock were exchanged, compared to its average volume of 2,921,520. Eli Lilly and Company has a 52 week low of $443.26 and a 52 week high of $966.10. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company’s 50 day moving average is $856.41 and its two-hundred day moving average is $770.39. The company has a market capitalization of $894.91 billion, a P/E ratio of 138.67, a PEG ratio of 2.07 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The business’s revenue was up 26.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on LLY. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,001.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. Citigroup lifted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, Berenberg Bank boosted their target price on Eli Lilly and Company from $850.00 to $1,000.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $858.72.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 over the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.